Sjoerd J Finnema1, Vladimir Stepanov2, Ryuji Nakao2, Anna W Sromek3, Tangzhi Zhang3, John L Neumeyer3, Susan R George4, Philip Seeman4, Michael G Stabin5, Cathrine Jonsson6, Lars Farde7, Christer Halldin2. 1. Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm, Sweden sjoerd.finnema@ki.se. 2. Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm, Sweden. 3. McLean Hospital, Harvard Medical School, Belmont, Massachusetts. 4. University of Toronto, Toronto, Ontario, Canada. 5. Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, Tennessee. 6. Department of Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden; and. 7. Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm, Sweden AstraZeneca, Translational Science Center at Karolinska Institutet, Stockholm, Sweden.
Abstract
UNLABELLED: PET has been used to examine changes in neurotransmitter concentrations in the living brain. Pioneering PET studies on the dopamine system have used D2 and D3 receptor (D2/D3) antagonists such as (11)C-raclopride. However, more recently developed agonist radioligands have shown enhanced sensitivity to endogenous dopamine. A limitation of available agonist radioligands is that they incorporate the short-lived radioisotope (11)C. In the current study, we developed the (18)F-labeled D2/D3 receptor agonist (R)-(-)-2-(18)F-fluoroethoxy-N-n-propylnorapomorphine ((18)F-MCL-524). METHODS: In total, 10 PET measurements were conducted on 5 cynomolgus monkeys. Initially, the binding of (18)F-MCL-524 was compared with that of (11)C-MNPA in 3 monkeys. Second, the specificity of (18)F-MCL-524 binding was examined in pretreatment studies using raclopride (1.0 mg/kg) and d-amphetamine (1.0 mg/kg). Third, a preliminary kinetic analysis was performed using the radiometabolite-corrected arterial input function of the baseline studies. Finally, 2 whole-body PET measurements were conducted to evaluate biodistribution and radiation dosimetry after intravenous injection of (18)F-MCL-524. RESULTS: (18)F-MCL-524 entered the brain and provided striatum-to-cerebellum ratios suitable for reliable quantification of receptor binding using the multilinear reference tissue model. Mean striatal nondisplaceable binding potential (BPND) values were 2.0 after injection of (18)F-MCL-524 and 1.4 after (11)C-MNPA. The ratio of the BPND values of (18)F-MCL-524 and (11)C-MNPA was 1.5 across striatal subregions. After administration of raclopride and d-amphetamine, the (18)F-MCL-524 BPND values were reduced by 89% and 56%, respectively. Preliminary kinetic analysis demonstrated that BPND values obtained with the 1-tissue- and 2-tissue-compartment models were similar to values obtained with the multilinear reference tissue model. Estimated radiation doses were highest for gallbladder (0.27 mSv/MBq), upper large intestine (0.19 mSv/MBq), and small intestine (0.17 mSv/MBq). The estimated effective dose was 0.035 mSv/MBq. CONCLUSION: The (18)F-labeled agonist (18)F-MCL-524 appears suitable for quantification of D2/D3 receptor binding in vivo, and the results encourage extension to human studies. The longer half-life of (18)F makes (18)F-MCL-524 attractive for studies on modulation of the dopamine concentration-for example, in combination with simultaneous measurement of changes in blood-oxygen-level-dependent signal using bimodal PET/functional MRI.
UNLABELLED: PET has been used to examine changes in neurotransmitter concentrations in the living brain. Pioneering PET studies on the dopamine system have used D2 and D3 receptor (D2/D3) antagonists such as (11)C-raclopride. However, more recently developed agonist radioligands have shown enhanced sensitivity to endogenous dopamine. A limitation of available agonist radioligands is that they incorporate the short-lived radioisotope (11)C. In the current study, we developed the (18)F-labeled D2/D3 receptor agonist (R)-(-)-2-(18)F-fluoroethoxy-N-n-propylnorapomorphine ((18)F-MCL-524). METHODS: In total, 10 PET measurements were conducted on 5 cynomolgus monkeys. Initially, the binding of (18)F-MCL-524 was compared with that of (11)C-MNPA in 3 monkeys. Second, the specificity of (18)F-MCL-524 binding was examined in pretreatment studies using raclopride (1.0 mg/kg) and d-amphetamine (1.0 mg/kg). Third, a preliminary kinetic analysis was performed using the radiometabolite-corrected arterial input function of the baseline studies. Finally, 2 whole-body PET measurements were conducted to evaluate biodistribution and radiation dosimetry after intravenous injection of (18)F-MCL-524. RESULTS: (18)F-MCL-524 entered the brain and provided striatum-to-cerebellum ratios suitable for reliable quantification of receptor binding using the multilinear reference tissue model. Mean striatal nondisplaceable binding potential (BPND) values were 2.0 after injection of (18)F-MCL-524 and 1.4 after (11)C-MNPA. The ratio of the BPND values of (18)F-MCL-524 and (11)C-MNPA was 1.5 across striatal subregions. After administration of raclopride and d-amphetamine, the (18)F-MCL-524 BPND values were reduced by 89% and 56%, respectively. Preliminary kinetic analysis demonstrated that BPND values obtained with the 1-tissue- and 2-tissue-compartment models were similar to values obtained with the multilinear reference tissue model. Estimated radiation doses were highest for gallbladder (0.27 mSv/MBq), upper large intestine (0.19 mSv/MBq), and small intestine (0.17 mSv/MBq). The estimated effective dose was 0.035 mSv/MBq. CONCLUSION: The (18)F-labeled agonist (18)F-MCL-524 appears suitable for quantification of D2/D3 receptor binding in vivo, and the results encourage extension to human studies. The longer half-life of (18)F makes (18)F-MCL-524 attractive for studies on modulation of the dopamine concentration-for example, in combination with simultaneous measurement of changes in blood-oxygen-level-dependent signal using bimodal PET/functional MRI.
Authors: Sjoerd J Finnema; Vladimir Stepanov; Anders Ettrup; Ryuji Nakao; Nahid Amini; Marie Svedberg; Charlotte Lehmann; Martin Hansen; Gitte M Knudsen; Christer Halldin Journal: Neuroimage Date: 2013-08-28 Impact factor: 6.556
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-13 Impact factor: 9.236
Authors: Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis Journal: Synapse Date: 2006-04 Impact factor: 2.562
Authors: J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley Journal: J Cereb Blood Flow Metab Date: 1990-09 Impact factor: 6.200
Authors: Neil Vasdev; Philip Seeman; Armando Garcia; Winston T Stableford; José N Nobrega; Sylvain Houle; Alan A Wilson Journal: Nucl Med Biol Date: 2007-01-17 Impact factor: 2.408
Authors: Vladimir Shalgunov; Jan-Peter van Wieringen; Henk M Janssen; P Michel Fransen; Rudi A J O Dierckx; Martin C Michel; Jan Booij; Philip H Elsinga Journal: EJNMMI Res Date: 2015-07-25 Impact factor: 3.138
Authors: Jan-Peter van Wieringen; Kora de Bruin; Henk M Janssen; P Michel Fransen; Anton G M Janssen; Peter A van Doremalen; Martin C Michel; Philip H Elsinga; Jan Booij Journal: Int J Mol Imaging Date: 2014-12-25
Authors: Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530
Authors: Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga Journal: Med Res Rev Date: 2018-11-18 Impact factor: 12.944